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Background
Psoriasis is a common inflammatory skin disease with a
multifactorial genetic basis. A dysregulated interplay
between keratinocytes and infiltrating immune cells
underlies the cutaneous inflammation in psoriasis.
Keratinocytes are important producers of antimicrobial
peptides such as hBD-2 and LL37 and cytokines such
as TNF-alpha, which are essential elements in this pro-
cess of cell-cell communication [1]. Recently, miRNA-
203 was identified as an important contributor to this
dysfunctional cross talk [2]. We have previously devel-
oped a new lipid-based nanosome (SECosome) that
enables the effective delivery of siRNA into human
skin [3]. The aim of this project is to knockdown
mRNA encoding hBD-2, LL37, TNF-alpha and
miRNA-203 by tranfection of keratinocytes with SECo-
somes for the delivery of siRNAs and anti-miRNAs.
Ultimately, we want to create a new therapy for psoria-
sis by intervening at genetic level by means of a topical
therapy.
Materials and Methods
An optimized cytokine mix was used to induce a psoriatic
phenotype starting from normal human keratinocytes.
Complexes of siRNA or anti-miRNA and SECosomes
were made and validated prior to transfection. 24h post-
tranfection, qPCR analysis was performed to evaluate
mRNA expression levels.
Results
Transfection experiments with the complexes showed a
stable knockdown efficiency of more than 80% of hBD-2,
LL37, TNF-alpha and miR-203 mRNA.
Conclusion
In this in vitro work we prepared and characterized
siRNA and anti-miRNA complexes with SECosomes
against hBD-2, LL37, TNF-alpha and miR-203 respec-
tively. These complexes efficiently knock-down the tar-
geted genes with concomitant downregulation of the
associated proteins. Hereafter we will test the therapeutic
applicability of our complexes in xenografted psoriatic
skin by topical application.
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